Diffuse large B-cell lymphoma
Not yet recruitingPhase II study of fixed‑dose, accelerated ramp‑up epcoritamab plus lenalidomide in patients with relapsed/refractory large B‑cell lymphoma after CAR‑T therapy
Phase II study of fixed‑dose, accelerated ramp‑up epcoritamab plus lenalidomide in patients with relapsed/refractory large B‑cell lymphoma after CAR‑T therapy
- Disease:Diffuse large B-cell lymphoma
- Substances:EpcoritamabLenalidomide
France- Participants:18–64 years · 65+ years
- Substances:Epcoritamab
- Sponsor:LYSARC







